Results 91 to 100 of about 170,256 (261)

Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study

Dermatology Practical & Conceptual
Introduction: Pembrolizumab is well-tolerated in pediatric patients with advanced tumors, consistent with results in adults. However, information on the safety and efficacy of adjuvant pembrolizumab in children and adolescents with melanoma is lacking.
Yu Du, Zhonghui Qi, Xianbin Liang , Jie Dai, Xiaoting Wei , Xue Bai , Lili Mao, Zhihong Chi , Chuanliang Cui, Bin Lian, Bixia Tang , Xuan Wang , Yu Chen , Jun Guo , Lu Si   +14 more
doaj   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

, 2020
BACKGROUND:Inhibition of the programmed cell death protein 1 (PD-1) pathway has demonstrated clinical benefit in metastatic urothelial cancer (mUC); however, response rates of 15% to 26% highlight the need for more effective therapies.
Shore, Neal, Tian Zhang, Alva, Ajjai S, Daniel J. George, Janet Staats, Munugalavadla, Veerendra, Raquel Izumi, O'Donnell, Peter H, Zhang, Tian, Cetnar, Jeremy, Ajjai S. Alva, Schmidt, Emmett V, Leonard J. Appleman, Appleman, Leonard J, Burke, John M, Guru P. Sonpavde, John M. Burke, Veerendra Munugalavadla, Milowsky, Matthew I, Matthew I. Milowsky, Weinhold, Kent J, Staats, Janet, Neal Shore, Fleming, Mark T, Priti Patel, Mark T. Fleming, Patel, Priti, Harrison, Michael R, Mortazavi, Amir, Sonpavde, Guru P, Jeremy Cetnar, Bojena Bitman, Amir Mortazavi, Cliburn Chan, Noah M. Hahn, Hahn, Noah M, Bitman, Bojena, Michael R. Harrison, Emmett V. Schmidt, Izumi, Raquel, Peter H. O'Donnell, Kent J. Weinhold, Chan, Cliburn, George, Daniel J   +43 more
core   +1 more source

Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose ...
Vaishali L. Chudasama, Helen Kastrissios, Hossam Kadry, Daping Zhang, Salaheldin Hamed, Srinivasu Poondru, Souvik Bhattacharya, Russ Wada, Amit Garg, Yen Lin Chia   +9 more
wiley   +1 more source

Efectividad de la inmunoterapia con pembrolizumab versus inmunoterapia con pembrolizumab combinada con quimiorradiación en el cáncer de cérvix. Revisión sistemática [PDF]

El cáncer de cérvix es una neoplasia maligna que se origina en las células del cuello del útero, ocasionado por una infección de transmisión sexual del virus del papiloma humano, es una patología de alta incidencia entre las mujeres alrededor del mundo ...
Rivera Chicaiza, Erika Johanna
core   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer

Journal for ImmunoTherapy of Cancer
Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Joshua J Meeks, Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy   +4 more
doaj   +1 more source

Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations [PDF]

Matthew Stewart,1 Jessica L Geiger2 1Department of Internal Medicine, Primary Care Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation ...
Stewart M, Geiger JL
core  

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma

Background: Adjuvant pembrolizumab improves disease-free and overall survival among patients with resected clear-cell renal-cell carcinoma. The hypoxia-inducible factor 2α inhibitor belzutifan has activity in advanced disease.
Miyake, Hideaki, Venugopal, Balaji, Iacovelli, Roberto, Choueiri, Toni K., Ferguson, Tom, Porta, Camillo, Uzzo, Robert G., Burgents, Joseph E., Sharma, Manish, Motzer, Robert J., Vázquez Limón, Juan Carlos, Lee, Jae Lyun, He, Zhisong, Hammers, Hans, Chahoud, Jad, Yip, Wesley, Chang, Yen-Hwa, Ye, Dingwei, McKay, Rana R., Liu, Hong, Caglevic, Christian, Ürün, Yüksel, Karam, Jose A., Rojas, Carlos, Verzoni, Elena, Suárez, Cristina, Powles, Thomas B.   +26 more
core   +1 more source